Status:
COMPLETED
Staphylococcal Acute Post-Operative PJI Treated With 'DAIR' And Impact Of Rifampin
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Bone and Joint Infection
Antibiotic Resistant Staphylococcus Aureus Infection
Eligibility:
All Genders
18-100 years
Brief Summary
S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.
Eligibility Criteria
Inclusion
- patients having had acute PJI (i.e. \<1 month following the implantation), DAIR with exchange of removal components) due to S. aureus and coagulase-negative staphylococci (2011-2016)
Exclusion
- None
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT03750721
Start Date
April 1 2018
End Date
May 1 2018
Last Update
November 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Lyon, France, 69004